Category: C.R. BardSyndicate content

PAD: Medtronic's In.Pact Admiral drug-eluting balloon bests Bard's Lutonix at 6 months

April 7, 2014 by Brad Perriello

Results from a clinical trial of Medtronic's In.Pact Admiral drug-eluting balloon for peripheral artery disease show lower target lesion revascularization rates than rival C.R. Bard's Lutonix DEB.

PAD: Medtronic's In.Pact Admiral drug-eluting balloon bests Bard's Lutonix at 6 months

Pelvic mesh lawsuits: Ethicon argues for federal court in 650 Okla. cases

February 21, 2014 by Brad Perriello

Some 650 lawsuits filed in an Oklahoma court over its pelvic mesh products ought to be treated as a mass action in federal court, Johnson & Johnson subsidiary Ethicon argued this week.

Pelvic mesh lawsuits: Ethicon argues for federal court in 650 Okla. cases

The plaintiffs in some 650 product liability lawsuits filed in an Oklahoma court over Ethicon's pelvic mesh products are improperly looking to exclude them from mass action status, the Johnson & Johnson (NYSE:JNJ) subsidiary argued this week in a federal appeals court.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Philly court sets up new pelvic mesh mass tort

February 20, 2014 by Brad Perriello

The Philadelphia Court of Common Pleas establishes a mass tort for all pelvic mesh lawsuits filed in its jurisdiction.

Philly court sets up new pelvic mesh mass tort

A Pennsylvania state judge ordered the creation of a mass tort this week to collect product liability lawsuits filed over pelvic mesh products against some of the largest names in medical devices.

Judge Arnold New, director of the Complex Litigation Center at the Philadelphia Court of Common Pleas, ordered Feb. 11 that "all currently filed pelvic mesh matters shall be transferred to the Complex Litigation Center Pelvic Mesh Mass Tort Program" for coordination, according to court documents.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Legal win, buyouts boost Bard's bottom line

February 3, 2014 by Brian Johnson

C.R. Bard's 4th-quarter bottom line gets a significant boost from a nearly $900 million legal payment from rival W.L. Gore and the more than $200 million gain from selling its electrophysiology business to Boston Scientific.

A nearly $900 million award from W.L. Gore boosted C.R. Bard's bottom line in Q4 as sales inch up 3% in 2013: Officials announce $500 million share buyback plan.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Bard mesh cases slated for discovery

January 27, 2014 by Brad Perriello

A federal judge orders the selection of 200 lawsuits for discovery proceedings in the multi-district litigation over C.R. Bard's Avaulta pelvic mesh products.

Bard mesh cases slated for discovery

The mass tort against C.R. Bard (NYSE:BCR) is about to generate an avalanche of paper after a federal judge ordered the plaintiffs and Bard to choose some 200 lawsuits for discovery.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Bellwether trial delayed in Bard Avaulta mesh case

January 10, 2014 by Brad Perriello

A bellwether trial in the multi-district litigation against C.R. Bard over its recalled Avaulta pelvic mesh is delayed after the wife of a key witness is hospitalized.

Bellwether trial delayed in Bard Avaulta mesh case

The urgent hospitalization of the wife of a key witness prompted a federal judge to indefinitely postpone a bellwether trial in the multi-district litigation over C.R. Bard's (NYSE:BCR) recalled Avaulta pelvic mesh.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Bard can't keep internal memos out of pelvic mesh trial

January 7, 2014 by Brad Perriello

C.R. Bard won't be allowed to exclude internal memos about its recalled Avaulta pelvic mesh from a bellwether product liability trial, a federal judge ruled last week.

Bard can't keep internal memos out of pelvic mesh trial

C.R. Bard (NYSE:BCR) won't be able to keep internal memos out of an upcoming bellwether trial over its recalled Avaulta pelvic mesh, a federal judge ruled last week.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp